FDA Classifies Boston Scientific Infinion CX Spinal Cord Stimulation Lead Recall as Class I in September 2026: 1,081 Serious Injuries Reported

FDA Classifies Boston Scientific Infinion CX Spinal Cord Stimulation Lead Recall as Class I

On September 3, 2026, the U.S. Food and Drug Administration (FDA) announced in its Medical Device Recalls and Early Alerts section that it classified Boston Scientific's recall of the Infinion CX Lead (spinal cord stimulation system lead) as a Class I recall. Class I is the most serious level in the FDA recall classification, meaning continued use of the device may cause serious injury or death. This recall applies only to unused lead products and does not include devices already implanted in patients.

Affected Models and Identification Information

The recall affects two Infinion CX Lead Kits:

• 50 cm model SC-2317-50, material number M365SC2317500, GTIN 08714729861614
• 70 cm model SC-2317-70, material number M365SC2317700, GTIN 08714729861638

The lead is a component of a spinal cord stimulation (SCS) system used to manage chronic pain in the back and limbs. The corresponding premarket approval (PMA) number is P030017.

Failure Cause and Reported Injuries

According to Boston Scientific, the lead body of the SCS system may experience mechanical stress at the anchoring site, leading to high impedance readings or lead fracture. Abnormal impedance may cause inadequate stimulation and may require additional intervention, including removal and replacement of the lead. As of May 27, 2026, the company reported 1,081 serious injuries and 0 deaths. The FDA database shows that the recall was initiated by the company on June 17, 2026, posted on August 5, 2026, with recall number Z-2879-2026. The status is classified and open.

Actions Requested by the Manufacturer

On June 17, 2026, Boston Scientific sent letters to all affected customers recommending the following:

• Immediately stop further use and distribution of the affected products and quarantine inventory.
• Return the products to Boston Scientific.
• Forward the notice to healthcare personnel within the facility who use the product, as well as to other institutions that may have received these systems.
• No additional patient monitoring is required beyond routine clinical follow-up.

The FDA states that leads already implanted in patients are not included in this recall.

Scope and Boundaries

This recall focuses on the U.S. market and the two unused models listed above. For patients who have already been implanted, the guidance is to continue routine clinical follow-up rather than proactive removal. Companies should note that the recall text does not require prophylactic replacement of implanted devices, nor does it make a consistency conclusion for all SCS products. Whether a company's own products are involved or whether corrective actions are needed still depends on internal assessment and the official source text.

AIMEILI Regulatory Interpretation

For regulatory affairs teams, this Class I recall highlights several critical points. First, the FDA's Class I designation is reserved for situations where there is a reasonable probability that use of the device will cause serious adverse health consequences or death. A Class I recall triggers heightened FDA oversight and typically requires robust field safety corrective action (FSCA) communications. Second, the reported 1,081 serious injuries underscore the importance of post-market surveillance and complaint handling for implantable leads, particularly those subject to mechanical stress at anchoring sites. Third, the recall covers only unused inventory, which means the manufacturer and distributors must have effective inventory segregation and traceability systems, including UDI/GTIN tracking, to identify and quarantine affected lots without disrupting care for implanted patients. Fourth, the recall number Z-2879-2026 and PMA P030017 indicate that the product is a Class III device subject to premarket approval; any design or manufacturing changes to address the root cause may require a PMA supplement or 30-day notice, depending on the change. Finally, the communication requirements—informing clinicians and other facilities—show the need for clear, prompt, and documented customer notifications in line with 21 CFR Part 806 and FDA guidance on recalls.

Business Impact

For manufacturers, distributors, CROs, and regulatory affairs teams, this recall has several business implications. Manufacturers of SCS leads or similar implantable devices should immediately assess whether their own products share similar design features, anchoring mechanisms, or materials that could be subject to the same failure mode. A gap assessment and risk analysis may be warranted, including a review of complaint trends, impedance-related failures, and lead fracture rates. Distributors and hospitals should expect customer notifications and may need to support inventory reconciliation, quarantine, and returns. For CROs and regulatory consultants, the recall may prompt clients to request recall readiness audits, FSCA procedure reviews, or mock recall exercises. In the broader market, Class I recalls can affect physician confidence, patient consent discussions, and reimbursement or hospital procurement decisions. Companies should also prepare for potential FDA inspections or requests for additional information related to the root cause and corrective actions. Proactive communication with competent authorities outside the U.S. may be necessary if the same products are distributed globally, as other regulators may initiate their own safety alerts or require local field safety notices. Ultimately, the recall reinforces the need for robust design controls, supplier management, and post-market risk management throughout the product lifecycle.

Sources and Verification

Sources:

• U.S. Food and Drug Administration (FDA) — Medical Device Recalls and Early Alerts: Spinal Cord Stimulator Recall: Boston Scientific Removes Infinion CX Lead (September 3, 2026). https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/spinal-cord-stimulator-recall-boston-scientific-removes-infinion-cx-lead
• U.S. Food and Drug Administration (FDA) — Medical Device Safety. https://www.fda.gov/medical-devices/medical-device-safety
• U.S. Food and Drug Administration (FDA) — Medical Device Recall Database (Event ID 98974). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?start_search=1&event_id=98974

Verification scope and access date: This review examined the FDA Medical Device Recalls and Early Alerts announcement page, the FDA Medical Device Safety listing page, and the FDA Medical Device Recall Database entry. Access date: October 5, 2026.

Applicability note: This article is an interpretation of publicly available FDA regulatory information and does not constitute a conclusion or commitment regarding any specific product, company, or registration application. Recall scope, models, and injury data are subject to the official source text and may change with subsequent official updates. Companies should rely on the official texts issued by the FDA and the manufacturer as the final basis.